Enteric Diseases Laboratory Branch (EDLB) preparing samples for DNA fingerprinting

Recent advancements in biotechnology have immense potential to help address many global problems; climate change, an aging society, food security, energy security, and infectious diseases.

Biotechnology is not to be confused with the closely related field of biosciences. While biosciences refer to all the sciences that study and understand life, biology, and biological organisms, biotechnology refers to the application of the knowledge of biosciences and other technologies to develop tech and commercial products. Biotechnology is the application of innovation to biosciences in a bid to solve real-world medical problems.

Throw Artificial Intelligence into the mix and we suddenly have a really interesting pot of broth. Several AI trends have already proven beneficial to the development of biotechnology. Dr. Nathan S. Bryan, an inventor, biochemist and professor, who made a name for himself as an innovator and pioneer in nitric oxide drug discovery, commercialization, and molecular medicine, offers his insights on these contributions.

Bryan has always held a strong interest in science and medicine and the innovations surrounding it, as signified in his insistence on the commercialization of his nitric oxide discoveries amid strong criticism and even opposition amongst his peers.. His strong entrepreneurial spirit as an academic was strange to many but has led to dozens of patents and product technology that have now generated over half a billion dollars in sales worldwide and an enterprise value of all his companies at over one billion dollars.

He is optimistic that AI has great potential to revolutionize the biotechnology industry if handled right.

Over the last 3 decades we have made tremendous strides in scientific discoveries that have become very impactful in drug development, health, wellness, and beauty, says Bryan.

All this was done mainly without Artificial Intelligence, imagine what we can achieve if the various concerns are handled and we can utilize the great advantage of machine learning to the fullest? Historically it takes an average of 17 years for a new discovery to come to market.Utilizing AI, it can happen much faster.Its a game-changer if I ever saw one.

AI-Generated Comprehensive Protein Map

Earlier this year the biotechnology world was rocked by an announcement by DeepMind, a subsidiary of Googles parent company, Alphabet. DeepMinds claimed to create the most comprehensive map of proteins to date using artificial intelligence.

Every investigation so far suggests that this is exactly what they have done. Before this breakthrough, determining the structure of a protein could only be done by a series of expensive and time-consuming experiments. However, DeepMind showed that relying on Alphafold, its AI software, it could produce accurate predictions of a proteins structure.

This extended the list of protein structures available in the public domain from 180,000, to a whopping 350,000 and everything can be downloaded by scientists for free. Perhaps the most profound part of this is that the list included 98% of all human proteins, which is astounding for scientists and researchers.

Bryan seems certain that this is just the tip of the iceberg for what is attainable. In his own words;

I can now go to the internet and download the most comprehensive list of human proteins ever into a memory stick. Frankly, that is an unexpected deluge of data, that we still dont know how to process, it is like taking us 10 years ahead in research. Its impact will probably not be felt in how people are treated instantly, but in the long run, it would have saved us a lot of years, says Bryan.

He continues, It only goes to show you why a lot of us in the scientific community are excited about the positive possibilities of AI. This is just the tip of the iceberg.Knowing a proteins structure helps us understand its function and how to repair it if an enzyme becomes dysfunctional.Many diseases, including many caused by a deficiency of nitric oxide are due to dysfunctional enzymes.

Open Source AI Platforms

Health care data and other scientific data are an ever-expanding library. The data is often scattered and complicated to arrange in any meaningful way without intense laborious work.

Scientists around the world are researching AI programs that can automate data maintenance and analysis. AI opensource platforms have become the answer to this desire in many ways. Open source platforms like H2O.ai, and DeepMIB have emerged in the last few years to free lab assistants from repetitive tasks such as data entry and analysis.

Bryan expands on the value of AI-open source platforms;

Research is a bigger deal than most people understand. A lot of tasks are heavy and repetitive, yet they have to be done repeatedly with the utmost care because every research failure is a lot of money and energy down the drain. Most basic science discoveries never lead to any effective medicine or therapy because it fails to translate into humans.

Dr. Nathan S. Bryan

He continues, In the science of nitric oxide, which is a gas that when produced is gone in less than a second, it has been very difficult to develop safe and effective therapeutics. We were the first to develop a solid dose of the nitric oxide gas.

Using AI platforms, we can monitor in real time changes in important vital signs and symptoms after administration to demonstrate safety and efficacy. This is really important since nitric oxide cant be measured in clinical labs like cholesterol or Vitamin D. Artificial intelligence is also quicker and more accurate in the analysis of other critical informatics.With the strain of manual labor gone, scientists and healthcare providers alike can focus on innovation.

Intelligent Disease Detection And Diagnosis

A recent study published in the Journal of the National Cancer Institute showed that the use of deep learning has been seen to achieve a breast cancer detection accuracy comparable to an average breast radiologist.

At the end of the day, every scientific sector and indeed every sector in the diverse industries depend on data to run effectively. The ability to organize and classify data into forums and subforums and to predict purported implications is one of the greatest advantages of Artificial Intelligence.

AI and IoT-powered wearables and appliances are another powerful way innovators are using AI to gather health data, in such a way that such data can be used to predict anomalies and early-stage diseases. Loss of nitric oxide is recognized as one of the earliest events in the onset and progression of every major chronic disease. Recognizing this prior to onset of symptoms is key to stopping the progression of disease. This will revolutionize health care and the costs associated with treating patients with advanced disease.

The possibilities are seemingly endless. According to Google, In their latest research, a neural network can be trained to detect signs of lung cancer faster and easier than trained radiologists. Developers are also trying to develop robust AI-driven software that can spot signs of a certain disease accurately in medical images such as, X-rays, MRIs, and CT scans.

Bryan explains, If we can eliminate mistakes in our approach and process, the world would be better for it. This is what I consider the greatest value AI brings. The ability to cross-reference the data of a patient against all other patients with similar diseases and to point out a single disimilarity can be the difference between losing a life and saving it.

What Does The Future Hold?

A lot of things have been touted. If algorithms can process all the information about our health, lifestyle, and the environment we live in, they can give suggestions on what to do to course-correct or to live healthier and hence make us live longer.

AI systems can help us stay fit, it can lighten the workload for doctors, reduce the workload for researchers and simplify the decision-making process. Its greatest contribution would be the ability to understand the vast amounts of scientific data that we have garnered from millennia of study and treatment. It is truly an exciting road of possibilities if we clear all the hurdles.

Bryan explains it well when he says; If we can deal with obstacles like biased data, extreme commercialization of AI systems, there is no way this would not be the catalyst for explosive scientific discoveries and more importantly translation of these discoveries into safe and effective therapeutics in this decade and beyond

As AI makes its journey from the periphery of sciences and healthcare to the mainstream, it seems that all we can do is marvel at the evolution and stand guard as well so that it doesn't become a double edged sword.

Link:
Artificial Intelligence Is Transforming Biotechnology, Especially When It Comes To Innovations In Nitric Oxide - Forbes

One of the issues that attracted agreement at the conference was the need to unite efforts regarding the dissemination of the benefits of plant biotechnology and the improvement of the regulatory aspects of its use in our country.

Science is a great ally in reaching agreements on possible ways to combat the effects of climate change. phrase from Carolina UrmenitaAnd Head of the Climate Change Office at the Ministry of Environment, summarizes the consensus among the speakers and speakers at the symposium Science, Agriculture and Climate Crisis, regarding the role that appropriate dissemination and linkage by the scientific world can play, to inform authorities, decision-makers and public opinion in general, of the potential that biotechnology can have, in the context of plant genetic improvement, as one of the options for addressing the challenges posed by climate change to agriculture Today.

Greetings from Alvaro Izaguirre, Executive Director of the Foundation for Agricultural Innovation, FIA, of the Ministry of AgricultureInitiated a symposium organized by ChileBio in which prominent national and international scholars and publishers participated, demonstrating various advances in Biotechnology for better food. Eyzaguirre commented: Science and agriculture must work together to make it more effective. This discipline plant biotechnology can be a strategic ally in the production of staple foods, commented. It is important for scientific communication to raise debate about the benefits of using these tools, especially when climate change is showing its effects, he added.

In this international symposium, the participation of the famous and famous scientist came to the fore. Jos Miguel Mollet, Chemistry Graduate and Ph.D. in Biochemistry and Molecular Biology from the University of ValenciaProfessor, Department of Biotechnology at the Polytechnic University of Valencia. He published a series of books and several articles in the press. He also highlighted the post Gabriel LyonAnd Chilean scientist, biochemist and physician in cell and molecular biology. A science communicator and author of popular science books such as Pop Science, What are snot? And Other Weird Questions I Sometimes Ask, among others.

Subsequently, a panel discussion was developed to which he joined Carolina Urmenita, Head of Climate Change Office at the Ministry of Environment and Francesca Castillo, Academician at Austral University in Chile and member of Agrupacin por la Biotecnologa y la Sostenibilidad Agroalimentaria (ABSA Chile), An exciting exchange of ideas, reflections and experiences on the role of plant biotechnology has developed.

Speakers have commented extensively on the difficulty of getting the message across from science that turns to evidence, in a world where emotion and shock seem to have more access to public opinion. Besides, they stressed the need for progress in Chile in organizing that allows us to use developments in the genetic improvement of vegetables in our cultivation, and to reach commercial stages, where today there is still an important crossroads.

CEO of ChileBIOAnd Miguel Angel Sanchez, He commented on the outcome of this meeting: It was a symposium that addressed the topics necessary to understand, discuss and look to the future regarding plant biotechnology. Both of them are of the necessity of communicating about the role of the various tools they possess, through misinformation and ignorance of their benefits. Climate change is here to stay, and the challenge of food production will increase to pursue Food security pathway. The development of plant varieties that are better adapted to climatic challenges, such as drought and heat tolerance and resistance to certain pests and diseases is a reality in the scientific world, he says.

One of the issues that attracted agreement at the conference was the need to unite efforts regarding the dissemination of the benefits of plant biotechnology and the improvement of the regulatory aspects of its use in our country. Sanchez concludes, There is a consensus in the scientific world about all the attributes of the different tools that biotechnology gives us, but there is an opinion of the public that views them with suspicion.. Gabriel Leon added: There is a schizophrenia between science and public opinion and this feeling has a very big impact.

Committee members agreed on the regulatory aspects that Chile needed to resolve in order for biotechnology solutions to be available for local production. On his part, he commented, Valuing biotechnology and making it available to small farmers is a viable path, in addition to creating an institutional framework that supports it. Dr. Francesca Castillo, researcher at the University of Austral and a spokesperson for the Association for Biotechnology and Food Sustainability (ABSA-Chile) who also stressed that there has to be a political will to sit down and discuss biotechnology, because its not all about genetics.

Read more from the original source:
A symposium entitled "Science, Agriculture and Climate Crisis", which highlighted the role of plant biotechnology in adapting agriculture to...

Studies to use genome wide functional genetic techniques to identify effective drug combinations and new drug targets for its lead clinical compound, LB-100

PASADENA, CA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, will present at the Benzinga Global Small Cap Conference being held virtually October 27-28, 2021.

Event and Registration: Benzinga Global Small Cap ConferencePresentation Date: Thursday, October 28, 2021Presentation Time: 11:55 a.m. ET

Lixte Founder and CEO John S. Kovach, M.D. will deliver a summary of the main features of its lead clinical compound, the PP2A inhibitor LB-100, and an overview of the Companys collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to identify the most promising drug combinations for LB-100 for cancer treatment. The pre-clinical studies are directed by Professor Ren Bernards (NKI), a leader in using genome wide functional genetic techniques to identify effective drug combinations, new drug targets, and mechanisms of resistance to cancer drugs.

Commenting on the collaboration, Dr. Kovach recently stated, We are extremely pleased to have the opportunity to collaborate with Professor Bernards and his excellent group. There are many pre-clinical studies demonstrating the ability of our lead compound, LB-100, an inhibitor of protein phosphatase 2A, to potentiate the activity of different cytotoxic drugs. Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound. A targeted approach to cancer treatment has been a long-standing research goal. Prof. Bernards approach makes it possible to select among a multitude of compounds those most likely to be effective when combined with a second drug and/or in cancers with a particular molecular abnormality. The possibility of identifying which drug in combination with LB-100 and in which type of tumor is most likely to be beneficial is a very exciting prospect.

Story continues

About Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases. A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the on switches because the off switches, especially the master off switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, damaged by chemo or other cancer therapies, to continue to replicate before repairing the damage, leading to the more efficient death and elimination of those cells from the body. Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds. The LB-100 compound, of which there are no competitors known to Lixte, is being tested in three clinical cancer treatment studies with others in planning. lixte.com

Forward-Looking Statements

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

Lixte Contact:info@lixte.comGeneral Phone: (631) 830-7092Investor Phone: (888) 289-5533

View post:
Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28 -...

Carla Padilla / El Vega[emailprotected] | Ensenada, British Columbia

Faced with the challenge of meeting the multiple demands of humanity, nearly seven thousand and 900 million individuals, to whom various climate change problems have been added to their growth, biotechnology is being positioned as a viable option to meet and gradually overcome them, giving way to the bioeconomy..

This was announced by Sal Fryer Velzquez, President of the National Network of Academia Biotechnology Tools for Sustainable Agriculture, during the opening of the 6th National Symposium on Biotechnology Tools for Sustainable Agriculture.

This event took place approximately from October 13 to 15, coordinated by the Department of Microbiology of Cicese, where he noted that despite the epidemic, food production and the general well-being of humanity does not stop.

The above is despite biotechnology and a backlog of tools that researchers use daily in the lab to seek improvements and impact in areas as diverse as biodiversity and environmental conservation.

In its current definition, stated, biotechnology is understood as the application of science and technology to biological systems and organisms, as well as to their parts, products, and models, in order to modify living or inert materials, including processes, to provide knowledge, goods and services.

He noted that biotechnology began with the domestication of animal and plant species nearly 10,000 years ago. Cheese and yoghurt were probably the first products made with a touch of biotechnology.

Basic and applied sciencesThe opening of this symposium, which was joined by more than 130 participants, was presided over by Rosa Moreau Breeze, Director of the Department of Experimental and Applied Biology at Cicese.

The program is centered on six keynote lectures, five talks with an applied focus on problems identified by national producers, 22 oral presentations, as well as 43 sharks in agricultural technology, agroecology, agrochemicals, biotic and abiotic stress, and biological control.

View post:
It's the science of biotechnology for the environment - Sunday Vision

The contract research organization (CRO) market is expected to reach US$ 88,835. 19 million in 2028 from US$ 50,093. 56 million in 2021; it is expected to grow at a CAGR of 8. 5% from 2021 to 2028.

New York, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Contract Research Organization Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and End User" - https://www.reportlinker.com/p06176777/?utm_source=GNW

The growth of the market is primarily attributed to the surge in R&D expenditures and outsourcing activities, and rise in the number of clinical trials.Moreover, increasing demand for specialized testing services is expected to foster market growth during the forecast period.

However, the dearth of skilled professionals hinders the market growth.Healthcare service providers have been focusing adapting to the challenging transformations triggered by the COVID-19 pandemic.

European countries such as Italy and Spain have registered the maximum number of deaths due to COVID-19.Clinical research plays a crucial role in developing diagnostics and medicines to fight the ongoing COVID-19 pandemic through rapid and accurate clinical trials, as well as in collecting robust and reliable outcomes in a variety of settings on a large scale.

Intensive global research collaborations among stakeholders and industries involving all countries are driving the market growth.

Based on type, the contract research organization (CRO) market is segmented into early phase services, clinical research services, laboratory services, and post-approval services.The early phase services segment further bifurcated into drug discovery services and preclinical services.

The clinical research services segment is the largest shareholder in the market and is expected to register the highest CAGR during the forecast period.By end user, the contract research organization (CRO) market is segmented into pharmaceutical and biotechnology companies, and medical devices companies.

The pharmaceutical and biotechnology companies segment holds a larger share in the market and is estimated to register a higher CAGR during 2021-2028.

The Association of Clinical Research Organization, European Federation of Pharmaceuticals Industries Associations, and US Food and Drug Administration are among the primary and secondary sources referred to while preparing the report on the contract research organization (CRO) market.Read the full report: https://www.reportlinker.com/p06176777/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Read more from the original source:
The pharmaceutical and biotechnology companies segment holds a larger share in the market and is estimated to register a higher CAGR during 2021-2028...

LOWELL, Mass., Oct. 25, 2021 /PRNewswire/ -- Alcyone Therapeutics ("Alcyone"), a biotechnology company developing precision therapies for neurological disorders with high unmet medical needs, today announced four key appointments to its executive leadership team, bringing significant expertise in neuroscience and genetic medicines development. Alcyone Therapeutics appointed Ottavio Vitolo, M.D., M.M.Sc., Chief Medical Officer and Global Head of R&D; Ravi Mehrotra, Ph.D., Chief Financial Officer and Head of Strategy; Susan D'Costa, Ph.D., Executive Vice President & Global Head of Technology; and Rachel Salzman, D.V.M., Executive Vice President of Portfolio, External Affairs & Development.

"I am thrilled to welcome Ottavio, Ravi, Susan and Rachel to Alcyone's executive management team. They are all accomplished leaders who bring diverse and vast expertise in the development of novel treatments for neurological disorders, in particular precision genetic therapies. They also all share the mission to build Alcyone into a premier organization that will bring transformative medicines to patients in need of better treatment options," said PJ Anand, Founder and Chief Executive Officer of Alcyone Therapeutics. "They will be integral to building our future as a leader in the development of central nervous system (CNS) therapies through a uniquely integrated, multi-disciplinary approach, as we leverage our FalconTM precision dosing technology and our multiple genetic therapy platforms."

About Alcyone TherapeuticsAlcyone Therapeutics is a biotechnology company developing precision therapies for neurological disorders with high unmet medical needs. The company integrates innovation in neuroscience, precision dosing platforms and in-house manufacturing capabilities to deliver transformative therapies to patients. Alcyone leverages the synergy between FalconTM, the company's proprietary intrathecal precising dosing platform that incorporates deep knowledge of CSF fluid dynamics, computational modeling and bioengineering, and multiple novel genetic therapy platforms developed at the Abigail Wexner Research Institute at Nationwide Children's Hospital (AWRI). This comprehensive approach allows for the optimization of central nervous system (CNS) dosing and delivery to better target the pathophysiology and anatomy specific to various neurological disease areas. Alcyone's lead programs target the treatment of Rett syndrome and IGHMBP2-Related Diseases (IRD). For more information, visit https://alcyonetx.com/, and follow Alcyone on LinkedIn and Twitter.

SOURCE Alcyone Therapeutics

Read the original:
Alcyone Therapeutics Strengthens Executive Team with New Senior Leadership Appointments - PRNewswire

Vir Biotechnology Inc. (NASDAQ:VIR) finished Friday with an addition of $0.28 to close at $40.21, an upside of 0.70 percent. An average of 480,040 shares of common stock have been traded in the last five days. There was a gain of $1.12 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 905,975 shares traded, while the 50-day average volume stands at 973,398.

VIR stock has decreased by -10.02% in the last month. The company shares reached their 1-month lowest point of $32.61 on 10/04/21. With the stock rallying to its 52-week high on 01/27/21, shares of the company touched a low of $25.31 and a high of $141.01 in 52 weeks. It has reached a new high 12 times so far this year and achieved 50.15% or $13.43 in price. In spite of this, the price is down -71.48% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor Warren Buffett has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored

3 days have passed since Vir Biotechnology Inc. (VIR) last reported insider trading activity. Pang Phillip, who is Chief Medical Officer, most recently acquired $4,000 shares at $39.65 per share on Oct 20. In this transaction, the insider spent $158,596. EVP, Research & CSO, Virgin Herbert, disposed of 1,375 shares at a price of $38.87 on Oct 19. The insider now owns more than $53,446 worth of shares. Prior to that, Director SATO VICKI L went on to Sale 15,174 shares at $39.56 each on Oct 19. An amount of $600,314 was transacted.

Vir Biotechnology Inc. (VIR) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 33.43 for the sector. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 29.58, the price-to-book (PB) ratio at 7.09.

The quick ratio of Vir Biotechnology Inc. for the three months ended June 29 was 5.90, and the current ratio was 5.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Vir Biotechnology Inc.s EBITDA margin for the year ending June 29 is -376.25%. Its gross profit as reported stood at $373.35 million compared to revenue of $76.37 million.

For investors, determining the potential profitability of the investment also depends on the performance of the companys management. In the past 12 months, Vir Biotechnology Inc.s return on assets was -29.30%. For the broader industry, ROE averaged -68.79 over the past year.

For the three-month period that ended June 29, Vir Biotechnology Inc. had $84.11 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $61.81 million in the quarter, while revenues of -$168.91 million were grew 150.43%. The analyst consensus anticipated Vir Biotechnology Inc.s latest quarter earnings to come in at -$0.48 per share, but it turned out to be $0.46, a 195.80% surprise. For the quarter, EBITDA amounted to $61.77 million. Shareholders own equity worth $130.61 million.

From a technical analysis perspective, lets take a brief look at Vir Biotechnology Inc. (VIR) price momentum. RSI 9-day as of the close on 22 October was 50.20%, suggesting the stock is Neutral, with historical volatility in this time frame at 30.25%.

As of today, VIRs price is $39.79 +2.87% or $1.12 from its 5-day moving average. VIR is currently trading -8.24% lower than its 20-day SMA and -9.60% lower than its 100-day SMA. However, the stocks current price level is -3.99% below the SMA50 and +36.12% above the SMA200.

The stochastic %K and %D were 82.66% and 72.96%, respectively, and the average true range (ATR) was 2.06. With the 14-day stochastic at 84.83% and the average true range at 2.34, the RSI (14) stands at 47.17%. The stock has reached -0.02 on the 9-day MACD Oscillator while the 14-day reading was at 1.37.

Goldman downgraded Vir Biotechnology Inc. (NASDAQ: VIR) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Vir Biotechnology Inc. (VIR) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell VIR, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a buy.

Analysts predict a range of price targets between $29.00 and $135.00, with a median target of $65.00. Taking a look at these predictions, the average price target given by analysts for Vir Biotechnology Inc. (VIR) stock is $68.14.

Originally posted here:
What The Financials Tell Us About Vir Biotechnology Inc. (VIR) - The Fosters Leader